


### PHARMACEUTICAL 2022



## Morphic Holding Inc. Rank 149 of 475



# RealRate

### PHARMACEUTICAL 2022



### Morphic Holding Inc. Rank 149 of 475

The relative strengths and weaknesses of Morphic Holding Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Morphic Holding Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 137% points. The greatest weakness of Morphic Holding Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is -7.2%, being 269% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	418,334
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	38,264
Liabilities, Non-Current	51,327
Other Assets	5,373
Other Compr. Net Income	-461
Other Expenses	0
Other Liabilities	0
Other Net Income	264
Property and Equipment	2,583
Research and Development	87,789
Revenues	19,794
Selling, General and Administrative Expense	27,811

Output Variable	Value in 1000 USD
Assets	426,290
Liabilities	89,591
Expenses	115,600
Stockholders Equity	336,699
Net Income	-95,542
Comprehensive Net Income	-95,772
Economic Capital Ratio	-7.2%